Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

Impact · against what's priced in

Xenetic Biosciences has reached a clinical milestone with the first patient dosed in a combination study with CAR T-cells for large B-cell lymphoma. While the study targets a high-need population, the stock is likely to remain range-bound until initial efficacy data is released in Q2 2027.

XBIO+0.40: No priced-in read yet

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

What matters in this story

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

What matters in this story

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

How each ticker is affected

Track these names every morning.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

What matters in this story

Next reads from the same story arc

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

What matters in this story

Next reads from the same story arc

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

How each ticker is affected

Track these names every morning.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow